Dual sequence-capture method for quantifying trans renal HPV DNA in urine

Patent metadata

Field	Value
Publication number	US-9809864-B2
Application number	US-201414772004-A
Country	US
Kind code	B2
Filing date	Mar 3, 2014
Priority date	Mar 1, 2013
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

Methods for the quantifying HPV Trans Renal DNA (TrDNA) from a urine sample from a subject using a dual sequence-capture approach are disclosed. The presently disclosed methods can be used to predict cancers including, but not limited to, cervical, anal, penile, and oropharyngeal cancers.

First claim

That which is claimed:

1. A sequence-based method for detecting HPV Trans-Renal DNA (TrDNA) in a subject, the method comprising:
(a) isolating one or more low molecular weight, fragmented cell-free nucleic acids from a urine sample from a subject thereby creating a library of the low molecular weight, fragmented cell-free nucleic acids;
(b) enriching the one or more low molecular weight fragmented cell-free nucleic acids isolated from the urine sample for HPV TrDNA using a high-risk HPV-specific solution-based capture method to enrich the HPV genome to produce one or more enriched HPV TrDNA, wherein enriching the one or more low molecular weight fragmented cell-free nucleic acids comprises:
(i) amplifying the HPV TrDNA in the library using ligation-mediated PCR (LM-PCR) to form a pre-capture PCR library;
(ii) hybridizing the pre-capture PCR library to a pool of HPV-specific capture probes specific for the HPV E1 region of the following HPV subtypes selected from the group consisting of: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, to form a post-capture PCR library;
(iii) amplifying the post-capture PCR library to produce one or more enriched HPV TrDNA; and
(iv) optionally repeating steps (iii) and (iv);

(d) adding at least one index to the one or more enriched HPV TrDNA;
(e) performing multiplexed sequencing of the one or more enriched HPV TrDNA having at least one index added thereto to produce a multiplexed nucleotide sequence;
(f) performing a sequence alignment between the multiplexed nucleotide sequence and the nucleotide sequence of one or more known HPV genotypes; and
(g) determining the percentage sequence identity between the multiplexed nucleotide sequence and the nucleotide sequence of the one or more known HPV genotypes;
wherein at least a 60% sequence identity between the multiplexed nucleotide sequence and the nucleotide sequence of the one or more known HPV genotypes means that HPV TrDNA has been detected in the subject.

2. The method of claim 1 , further comprising performing quantitative PCR (qPCR) to amplify the one or more enriched HPV TrDNA.

3. The method of claim 2 , wherein amplifying the one or more enriched HPV TrDNA amplifies the E1 region of at least one HPV genotype.

4. The method of claim 2 , wherein amplifying the one or more enriched HPV TrDNA amplifies most or all of the genotype-specific regions of at least one HPV genome.

5. The method of claim 1 , wherein the low molecular weight, fragmented cell-free nucleic acids are from about 150 to about 250 base pairs.

6. The method of claim 1 , wherein isolating the one or more low molecular weight, fragmented cell-free nucleic acids from the urine sample occurs by separating the nucleic acids from the urine by applying the nucleic acids to a container comprising Q-Sepharose and/or silica resin substrate, allowing the nucleic acids to bind to the substrate, washing the substrate, and then eluting the nucleic acids with an elution buffer.

7. The method of claim 1 , wherein the subject is human.

8. The method of claim 1 , wherein the method is for detecting methylated HPV Trans-Renal DNA (TrDNA) in a subject, and wherein prior to step (d) the post-capture library is treated with a bisulfite compound and is amplified using PCR to form one or more amplified methylated HPV TrDNA; and further wherein at least a 70% sequence identity between the multiplexed nucleotide sequence and the nucleotide sequence of the one or more known methylated HPV genotypes means that methylated HPV TrDNA has been detected in the subject.

9. A sequence-based method for predicting or screening for cancer by detecting high-risk HPV Trans-Renal DNA (TrDNA) in a subject, the method comprising:
(a) isolating one or more low molecular weight, fragmented cell-free nucleic acids from a urine sample from a subject thereby creating a library of the low molecular weight, fragmented cell-free nucleic acids;
(b) enriching the one or more low molecular weight fragmented cell-free nucleic acids isolated from the urine sample for HPV TrDNA using a high-risk HPV-specific solution-based capture method to enrich the HPV genome to produce one or more enriched HPV TrDNA, wherein enriching the one or more low molecular weight fragmented cell-free nucleic acids comprises:
(i) amplifying the HPV TrDNA in the library using ligation-mediated PCR (LM-PCR) to form a pre-capture PCR library;
(ii) hybridizing the pre-capture PCR library to a pool of HPV-specific capture probes specific for the HPV E1 region of the following HPV subtypes selected from the group consisting of: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, to form a post-capture PCR library;
(iii) amplifying the post-capture PCR library to produce one or more enriched HPV TrDNA; and
(iv) optionally repeating steps (iii) and (iv);

(d) adding at least one index to the one or more enriched HPV TrDNA;
(e) performing multiplexed sequencing of the one or more enriched HPV TrDNA having at least one index added thereto to produce a multiplexed nucleotide sequence;
(f) performing a sequence alignment between the multiplexed nucleotide sequence and the nucleotide sequence of one or more known HPV genotypes; and
(g) determining the percentage sequence identity between the multiplexed nucleotide sequence and the nucleotide sequence of the one or more known HPV genotypes;
wherein at least a 60% sequence identity between the multiplexed nucleotide sequence and the nucleotide sequence of the one or more known high-risk HPV genotypes is indicative that the subject has or is at risk for developing a cancer.

10. The method of claim 9 , wherein the low molecular weight, fragmented cell-free nucleic acids are from about 150 to about 250 base pairs.

11. The method of claim 9 , wherein the cancer is selected from the group consisting of cervical, anal, penile, and oropharyngeal.

12. The method of claim 9 , wherein isolating the one or more low molecular weight, fragmented cell-free nucleic acids from the urine sample occurs by separating the nucleic acids from the urine by applying the nucleic acids to a container comprising Q-Sepharose and/or silica resin substrate, allowing the nucleic acids to bind to the substrate, washing the substrate, and then eluting the nucleic acids with an elution buffer.

13. The method of claim 9 , wherein the subject is human.

14. The method of claim 9 , wherein the method is for predicting or screening for cancer by detecting high-risk methylated HPV Trans-Renal DNA (TrDNA) in a subject, and wherein prior to step (d) the post-capture library is treated with a bisulfate compound and is amplified using PCR to form one or more amplified methylated HPV TrDNA; and further wherein at least a 70% sequence identity between the multiplexed nucleotide sequence and the nucleotide sequence of the one or more known high-risk methylated HPV genotypes is indicative that the subject has or is at risk for developing a cancer.

15. A method for detecting methylated human Trans-Renal DNA (TrDNA) in a subject, the method comprising:
(a) isolating one or more low molecular weight, fragmented cell-free nucleic acids from a urine sample from a subject thereby creating a library of the low molecular weight, fragmented cell-free nucleic acids;
(b) enriching the one or more low molecular weight fragmented cell-free nucleic acids isolated from the urine sample for HPV TrDNA using a high-risk HPV-specific solution-based capture method to enrich the HPV genome to produce one or more enriched HPV TrDNA, wherein enriching the one or more low molecular weight fragmented cell-free nucleic acids comprises:
(i) amplif

Assignees

• Univ Johns Hopkins

Inventors

• Preston Rafael Guerrero
• Jedlicka Anne
• Sidransky David

Classifications

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q1/708 Primary

  for papilloma · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/154

  Methylation markers · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title